Safety and efficacy of single-agent ibrutinib in patients with relapsed/refractory ( R/R) marginal zone lymphoma ( MZL): A multicenter, open-label, phase 2 study.

Authors :: Collins, G.P.
Noy, A.
Vos, S.
Thieblemont, C.
Martin, P.
Flowers, C.
Morschhauser, F.
Ma, S.
Coleman, M.
Peles, S.
Smith, S.
Barrientos, J.
Smith, A.
Munneke, B.
Dimery, I.
Beaupre, D.
Chen, R.
Source :: Hematological Oncology; Jun2017 Supplement, Vol. 35, p211-212, 2p
Publication Year :: 2017

Full Text Access

Tools